Anebulo Pharmaceuticals, Inc. anticipated releasing topline data from Part A of its ongoing Phase 2 study of ANEB-001 on July 5th. The results of the study, conducted in sixty healthy subjects challenged with delta-9-tetrahydrocannabinol, better known as THC, will be used to design the next step forward in the clinical trial for ANEB-001 as a potential treatment of ACI.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.03 USD | 0.00% | +0.50% | -16.12% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.12% | 52.64M | |
+35.02% | 52.85B | |
-7.24% | 38.87B | |
+35.37% | 38.24B | |
-10.77% | 26.79B | |
+12.00% | 26.16B | |
-18.19% | 19.9B | |
+36.43% | 13.18B | |
+29.36% | 12.24B | |
-2.90% | 11.79B |
- Stock Market
- Equities
- ANEB Stock
- News Anebulo Pharmaceuticals, Inc.
- Anebulo Pharmaceuticals, Inc. Announces Topline Data for ANEB-001 from an Ongoing Phase 2 Clinical Trial for Acute Cannabinoid Intoxication on Tuesday July 5, 2022